Filtered By:
Management: National Institutes of Health (NIH)
Procedure: Transplants
This page shows you your search results in order of date.
Order by Relevance | Date
Total 176 results found since Jan 2013.
Comparative Analysis of the Results of Stroke Treatment With Multiple Administrations of Wharton's Jelly Mesenchymal Stem Cells-Derived HE-ATMP and Standard Conservative Treatment: Case Series Study
Cell Transplant. 2023 Jan-Dec;32:9636897231195145. doi: 10.1177/09636897231195145.ABSTRACTStroke remains still the leading cause of long-term disability worldwide. Although interventions such as early reperfusion, intravenous thrombolysis, and endovascular revascularization have shown neurological benefit in stroke patients, there is still lack of effective treatment enabling regeneration of nervous tissue after cerebral ischemic episodes. Cell therapy is an evolving opportunity for stroke survivors with residual neurological deficits. The purpose of this study was to evaluate safety and potential efficacy of multiple admi...
Source: Cell Transplantation - August 30, 2023 Category: Cytology Authors: Olga Milczarek Jakub Swad źba Patrycja Swad źba Anna Starowicz-Filip Roger M Krzy żewski Stanis ław Kwiatkowski Marcin Majka Source Type: research
The improving Medication Adherence in Adolescents and young adults following Liver Transplantation (iMALT) multisite trial: Design and trial implementation considerations
DISCUSSION: Improving Medication Adherence in adolescent Liver Transplant includes several innovative design elements. The use of a validated, objective adherence index to survey a large cohort of transplant recipients allows the teams to avoid bias inherent in both convenience sampling and referral-based recruitment and enroll only patients whose computed index indicates substantially increased risk of rejection. The remote intervention paradigm helps to engage patients who are by definition hard to engage. The use of an objective, masked medical (rather than behavioral) outcome measure reduces the likelihood of biases re...
Source: Clinical Trials - June 3, 2023 Category: Research Authors: Eyal Shemesh Sarah Duncan-Park George Mazariegos Rachel Annunziato Ravinder Anand Miguel Reyes-Mugica Jeff Mitchell Benjamin L Shneider for iMALT Source Type: research
Is low-risk status a surrogate outcome in pulmonary arterial hypertension? An analysis of three randomised trials
Lancet Respir Med. 2023 May 22:S2213-2600(23)00155-8. doi: 10.1016/S2213-2600(23)00155-8. Online ahead of print.ABSTRACTBACKGROUND: Targeting short-term improvements in multicomponent risk scores for mortality in patients with pulmonary arterial hypertension (PAH) could result in improved long-term outcomes. We aimed to determine whether PAH risk scores were adequate surrogates for clinical worsening or mortality outcomes in PAH randomised clinical trials (RCTs).METHODS: We performed an individual participant data meta-analysis of RCTs selected from PAH trials provided by the US Food and Drug Administration (FDA). We calcu...
Source: Respiratory Care - May 25, 2023 Category: Respiratory Medicine Authors: Bryan S Blette Jude Moutchia Nadine Al-Naamani Corey E Ventetuolo Chao Cheng Dina Appleby Ryan J Urbanowicz Jason Fritz Jeremy A Mazurek Fan Li Steven M Kawut Michael O Harhay Source Type: research
Gastrointestinal and Hepatic Manifestations of Chronic Granulomatous Disease
J Allergy Clin Immunol Pract. 2023 Jan 13:S2213-2198(23)00050-8. doi: 10.1016/j.jaip.2022.12.039. Online ahead of print.ABSTRACTChronic granulomatous disease (CGD) is a rare inborn error of immunity, resulting from a defect in nicotinamide adenine dinucleotide phosphate (NADPH) oxidation and decreased production of phagocyte reactive oxygen species. The main clinical manifestations are recurrent infections and chronic inflammatory disorders. Current approaches to management include antimicrobial prophylaxis and control of inflammatory complications. Hematopoietic stem cell transplantation (HSCT) or gene therapy can provide...
Source: Cancer Control - January 16, 2023 Category: Cancer & Oncology Authors: Alexander H Yang Brigit Sullivan Christa S Zerbe Suk See De Ravin Andrew M Blakely Martha M Quezado Beatriz E Marciano Jamie Marko Alexander Ling David E Kleiner John I Gallin Harry L Malech Steven M Holland Theo Heller Source Type: research
Results of Multicenter Phase II Study With Imatinib Mesylate in Allogeneic Recipients With Steroid-Refractory Chronic GVHD
Cell Transplant. 2022 Jan-Dec;31:9636897221113789. doi: 10.1177/09636897221113789.ABSTRACTIn this multicenter phase II study, we evaluated the safety and efficacy of imatinib in patients with steroid-resistant chronic graft-versus-host disease (cGVHD) and evaluated the quality of life (QOL) of the enrolled patients using the Short Form 36 (SF-36) health survey questionnaire. Thirty-six patients who were diagnosed with steroid-refractory cGVHD and treated with imatinib between March 2013 and February 2019 received 100 mg/day of imatinib for 2 weeks. Depending on the patient's condition and investigator's decision, the imati...
Source: Cell Transplantation - July 21, 2022 Category: Cytology Authors: Dong Won Baek Hee Jeong Cho Ju-Hyung Kim Jae Sook Ahn Hyeoung-Joon Kim Sung Nam Lim Jun Won Cheong Sung-Yong Kim Ho Sup Lee Jong Ho Won Ho-Young Yhim Sang Kyun Sohn Joon Ho Moon Source Type: research
Weekly Overseas Health IT Links – 26th March, 2022.
Here are a few I came across last week.Note: Each link is followed by a title and few paragraphs. For the full article click on the link above title of the article. Note also that full access to some links may require site registration or subscription payment.-----https://mhealthintelligence.com/news/55-of-telehealth-providers-frustrated-with-overblown-patient-expectations55% of Telehealth Providers Frustrated With Overblown Patient ExpectationsProviders also cited their ability to provide quality care and technical difficulties as among their top frustrations with telehealth, a new survey shows.ByAnuja VaidyaMarch 18, 202...
Source: Australian Health Information Technology - March 26, 2022 Category: Information Technology Authors: Dr David G More MB PhD Source Type: blogs
Final Results of Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells in Acute Ischemic Stroke (AMASCIS): A Phase II, Randomized, Double-Blind, Placebo-Controlled, Single-Center, Pilot Clinical Trial
We report the final trial results after 24 months of follow-up. Recruitment began in December 2014 and stopped in December 2017 after 19 of 20 planned patients were included. Six patients did not receive study treatment: two due to technical issues and four for acquiring exclusion criteria after randomization. The final study sample was composed of 13 patients (4 receiving AD-MSCs and 9 placebo). One patient in the placebo group died within the first week after study treatment delivery due to sepsis. Two non-treatment-related serious AEs occurred in the AD-MSC group and nine in the placebo group. The total number of AEs an...
Source: Cell Transplantation - March 18, 2022 Category: Cytology Authors: Elena de Celis-Ruiz Blanca Fuentes Mar ía Alonso de Leciñana Mar ía Gutiérrez-Fernández Alberto M Borobia Raquel Guti érrez-Zúñiga Gerardo Ruiz-Ares Laura Otero-Ortega Fernando Laso-Garc ía Mari Carmen G ómez-de Frutos Exuperio D íez-Tejedor Source Type: research
